Brother Enterprises Holding (002562.SZ): The listing application for iodine pamoate raw material pharmaceutical products has been approved.

Brother Enterprises Holding (002562.SZ) announced that its wholly-owned subsidiary, Jiangxi Brother Pharmaceutical Co., Ltd. ("Brother Pharmaceuticals"), recently received the approval notice for the application of Chemical Raw Materials for the listing of the product "Iopromide" from the National Medical Products Administration. The approval of the Iopromide raw material product indicates that the raw material has met the national standards for raw material evaluation techniques. After meeting the requirements of drug production quality management standards, it can be produced and sold in the domestic market. This approval will have a positive impact on the company's capacity release for the Iopromide raw material project and further market expansion.